Beth Israel Deaconess Medical Center, Inc.; Inc.;The General Hospital Corporation D/B/A;Dana Farber Cancer Institute;Dana Farber Cancer Institute, Inc.
发明人:
Janne, Pasi A.,Engelman, Jeffrey,Cantley, Lewis C.
申请号：
AU2013203111
公开号：
AU2013203111B2
申请日:
2013.04.09
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
#$%^&*AU2013203111B220151008.pdf#####ABSTRACT Provided herein are methods for treating cancer that is resistant to treatment with an anti- ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene 5 amplification. The methods involve administering to a subject a combination of an anti- ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or P13 kinase mediated signaling in a cancer cell.
